Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer
about
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancerCabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experienceA human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinomaUse of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer TherapyA phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancerThe biology of castration-resistant prostate cancerThe systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer.Curcumin mediates reversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Met expression in DU145 cells.Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagyRapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo.Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic miceThe osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer.Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?Emerging drugs for prostate cancer.Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.Current role of cabozantinib in metastatic castration-resistant prostate cancer.Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?Promising new strategies for hepatocellular carcinoma.Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: a meta-analysis.
P2860
Q26795625-CE60D8E2-BB84-42D7-A4CE-B07C62000532Q28072166-0D0ED360-A2B5-493C-B8EF-F8FBBCF2D0ACQ28487973-FC259219-C9EB-4BF5-831C-03AEBD0EC955Q33859472-49B90D30-141D-4CD4-B752-652CF0F45135Q34657338-B06E979E-EA52-4B08-9D6D-0603ECEFDF36Q35039889-B56A2452-BDBA-4A8E-8B26-061174694325Q35181099-D596AB9F-2009-4D72-B253-9A3F31581A13Q36524826-D45B626C-B1D4-45FA-87B5-C9C9D76AF8E4Q36557246-61BE63CC-BB36-4C05-A7B3-6F2A178609C6Q36621024-D59D4D9C-E0E9-4415-ABFA-48E590E8AE76Q36941168-3656C182-8D97-4142-B8C1-09244A8BE23CQ37615017-BE9685EC-280F-4E18-B24A-FF29E94DCC08Q37665068-76EA0B7D-DB1B-48CA-8029-39D57E99ED0FQ38166018-CE1EEA14-4E12-451B-94EB-22907A339ABCQ38177689-C727D742-410E-46FE-98D3-85ECFD17D7CDQ38317384-52662A58-DB1A-443C-A0ED-984801A9A95BQ38700342-10D3D26C-8889-4AE8-8E0C-0D2C000AA440Q38723404-5B47327C-8E86-4E3A-BC2C-3F8E8D787B4DQ38936589-978AB826-8EAA-436A-8E0A-1517F8CF3253Q54759427-90B05D86-B568-4F52-BEEC-986EACDA8531
P2860
Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Targeting MET and vascular end ...... tion-resistant prostate cancer
@en
type
label
Targeting MET and vascular end ...... tion-resistant prostate cancer
@en
prefLabel
Targeting MET and vascular end ...... tion-resistant prostate cancer
@en
P2860
P1433
P1476
Targeting MET and vascular end ...... tion-resistant prostate cancer
@en
P2093
Matthew R Smith
Richard J Lee
P2860
P356
10.1097/PPO.0B013E318281E280
P577
2013-01-01T00:00:00Z